Медицинский вестник Юга России (Jul 2022)

Сurrent status of adrenocortical cancer therapy

  • S. N. Fogt,
  • V. V. Kalugina,
  • N. V. Vorokhobina,
  • A. V. Kuznetsova,
  • I. P. Serebryakova

DOI
https://doi.org/10.21886/2219-8075-2022-13-2-154-161
Journal volume & issue
Vol. 13, no. 2
pp. 154 – 161

Abstract

Read online

Adrenocarcinoma is a rare adrenal disease with an unfavorable prognosis. Adrenocortical cancer therapy is characterized by insufficient effectiveness. This review covers the generally accepted adrenocortical carcinoma therapy methods -mitotane alone or in combination with chemotherapeutic agents. It also provides perspectives from the novel agents` studies in adrenocarcinoma patients. Information about the use of insulin-like growth factor inhibitors, multikinase inhibitors, anti-PD-1/PD-L1 is given.

Keywords